H

ello, everyone, and how are you today? We are doing much better, thank you very much, now that the municipal work crew has departed, which allows the Pharmalot campus to be restored to its usual serene state. The official mascots are especially happy since they can snooze comfortably once again. And we are celebrating with a cup of delicious stimulation — cinnamon coffee roll, if you must know. Meanwhile, here are some tidbits. Enjoy your day and do drop us a line when something juicy arises. We will not allow spy agencies to learn your identity …

Valeant Pharmaceuticals reached a deal to sell its iNova Pharmaceuticals unit for $930 million, the latest attempt by the beleaguered drug maker to rid itself of a burdensome debt load, the Wall Street Journal notes. iNova, which operates in more than 15 countries, sells prescription and over-the-counter products in areas such as weight management, pain management, cardiology, and cough and cold.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy